@article{aidelsburger_cost-effectiveness_2014,
	title = {Cost-effectiveness of childhood rotavirus vaccination in {Germany}},
	volume = {32},
	issn = {0264-410X},
	doi = {10.1016/j.vaccine.2014.01.061},
	abstract = {Background: Rotavirus (RV) causes a highly contagious gastroenteritis especially in children under five years of age. Since 2006 two RV-vaccines are available in Europe (Rotarix (R) and RotaTeq (R)). To support informed decision-making within the German Standing Committee on Vaccination (STIKO) the cost-effectiveness of these two vaccines was evaluated for the German healthcare setting. Methods: A Markov model was developed to evaluate the cost-effectiveness from the statutory health insurance (SHI) and from the societal perspective. RV-cases prevented, RV-associated hospitalizations avoided, and quality-adjusted life years (QALY) gained were considered as health outcomes. RV-incidences were calculated based on data from the national mandatory disease reporting system. RV-vaccine efficacy was determined as pooled estimates based on data from randomized controlled trials. Vaccine list prices and price catalogues were used for cost-assessment. Effects and costs were discounted with an annual discount rate of 3\%. Results: The base-case analysis (SHI-perspective) resulted in an incremental cost-effectiveness and costutility ratio for Rotarix of is an element of 184 per RV-case prevented, E 2457 per RV-associated hospitalization avoided, and E 116,973 per QALY gained. For RotaTeq (R), the results were E 234 per RV-case prevented, is an element of 2622 per RV-associated hospitalization avoided, and is an element of 142,732 per QALY gained. Variation of various parameters in sensitivity analyses showed effects on the ICERs without changing the overall trend of base-case results. When applying base-case results to the 2012 birthcohort in Germany with 80\% vaccination coverage, an estimated 206,000-242,000 RV-cases and 18,000 RV-associated hospitalizations can be prevented in this birthcohort over five years for an incremental cost of 44.5-48.2 million is an element of. Conclusion: Our analyses demonstrate that routine RV-vaccination could prevent a substantial number of RV-cases and hospitalizations in the German healthcare system, but the saved treatment costs are counteracted by costs for vaccination. However, with vaccine prices reduced by similar to 62-66\%, RV-vaccination could even become a cost-saving preventive measure. (C) 2014 Elsevier Ltd. All rights reserved.},
	number = {17},
	journal = {Vaccine},
	author = {Aidelsburger, Pamela and Grabein, Kristin and Boehm, Katharina and Dietl, Markus and Wasem, Juergen and Koch, Judith and Ultsch, Bernhard and Weidemann, Felix and Wichmann, Ole},
	month = apr,
	year = {2014},
	note = {WOS:000336016700008},
	pages = {1964--1974},
}

{"_id":"CbrwvoagXJwCJgmP7","bibbaseid":"aidelsburger-grabein-boehm-dietl-wasem-koch-ultsch-weidemann-etal-costeffectivenessofchildhoodrotavirusvaccinationingermany-2014","author_short":["Aidelsburger, P.","Grabein, K.","Boehm, K.","Dietl, M.","Wasem, J.","Koch, J.","Ultsch, B.","Weidemann, F.","Wichmann, O."],"bibdata":{"bibtype":"article","type":"article","title":"Cost-effectiveness of childhood rotavirus vaccination in Germany","volume":"32","issn":"0264-410X","doi":"10.1016/j.vaccine.2014.01.061","abstract":"Background: Rotavirus (RV) causes a highly contagious gastroenteritis especially in children under five years of age. Since 2006 two RV-vaccines are available in Europe (Rotarix (R) and RotaTeq (R)). To support informed decision-making within the German Standing Committee on Vaccination (STIKO) the cost-effectiveness of these two vaccines was evaluated for the German healthcare setting. Methods: A Markov model was developed to evaluate the cost-effectiveness from the statutory health insurance (SHI) and from the societal perspective. RV-cases prevented, RV-associated hospitalizations avoided, and quality-adjusted life years (QALY) gained were considered as health outcomes. RV-incidences were calculated based on data from the national mandatory disease reporting system. RV-vaccine efficacy was determined as pooled estimates based on data from randomized controlled trials. Vaccine list prices and price catalogues were used for cost-assessment. Effects and costs were discounted with an annual discount rate of 3%. Results: The base-case analysis (SHI-perspective) resulted in an incremental cost-effectiveness and costutility ratio for Rotarix of is an element of 184 per RV-case prevented, E 2457 per RV-associated hospitalization avoided, and E 116,973 per QALY gained. For RotaTeq (R), the results were E 234 per RV-case prevented, is an element of 2622 per RV-associated hospitalization avoided, and is an element of 142,732 per QALY gained. Variation of various parameters in sensitivity analyses showed effects on the ICERs without changing the overall trend of base-case results. When applying base-case results to the 2012 birthcohort in Germany with 80% vaccination coverage, an estimated 206,000-242,000 RV-cases and 18,000 RV-associated hospitalizations can be prevented in this birthcohort over five years for an incremental cost of 44.5-48.2 million is an element of. Conclusion: Our analyses demonstrate that routine RV-vaccination could prevent a substantial number of RV-cases and hospitalizations in the German healthcare system, but the saved treatment costs are counteracted by costs for vaccination. However, with vaccine prices reduced by similar to 62-66%, RV-vaccination could even become a cost-saving preventive measure. (C) 2014 Elsevier Ltd. All rights reserved.","number":"17","journal":"Vaccine","author":[{"propositions":[],"lastnames":["Aidelsburger"],"firstnames":["Pamela"],"suffixes":[]},{"propositions":[],"lastnames":["Grabein"],"firstnames":["Kristin"],"suffixes":[]},{"propositions":[],"lastnames":["Boehm"],"firstnames":["Katharina"],"suffixes":[]},{"propositions":[],"lastnames":["Dietl"],"firstnames":["Markus"],"suffixes":[]},{"propositions":[],"lastnames":["Wasem"],"firstnames":["Juergen"],"suffixes":[]},{"propositions":[],"lastnames":["Koch"],"firstnames":["Judith"],"suffixes":[]},{"propositions":[],"lastnames":["Ultsch"],"firstnames":["Bernhard"],"suffixes":[]},{"propositions":[],"lastnames":["Weidemann"],"firstnames":["Felix"],"suffixes":[]},{"propositions":[],"lastnames":["Wichmann"],"firstnames":["Ole"],"suffixes":[]}],"month":"April","year":"2014","note":"WOS:000336016700008","pages":"1964–1974","bibtex":"@article{aidelsburger_cost-effectiveness_2014,\n\ttitle = {Cost-effectiveness of childhood rotavirus vaccination in {Germany}},\n\tvolume = {32},\n\tissn = {0264-410X},\n\tdoi = {10.1016/j.vaccine.2014.01.061},\n\tabstract = {Background: Rotavirus (RV) causes a highly contagious gastroenteritis especially in children under five years of age. Since 2006 two RV-vaccines are available in Europe (Rotarix (R) and RotaTeq (R)). To support informed decision-making within the German Standing Committee on Vaccination (STIKO) the cost-effectiveness of these two vaccines was evaluated for the German healthcare setting. Methods: A Markov model was developed to evaluate the cost-effectiveness from the statutory health insurance (SHI) and from the societal perspective. RV-cases prevented, RV-associated hospitalizations avoided, and quality-adjusted life years (QALY) gained were considered as health outcomes. RV-incidences were calculated based on data from the national mandatory disease reporting system. RV-vaccine efficacy was determined as pooled estimates based on data from randomized controlled trials. Vaccine list prices and price catalogues were used for cost-assessment. Effects and costs were discounted with an annual discount rate of 3\\%. Results: The base-case analysis (SHI-perspective) resulted in an incremental cost-effectiveness and costutility ratio for Rotarix of is an element of 184 per RV-case prevented, E 2457 per RV-associated hospitalization avoided, and E 116,973 per QALY gained. For RotaTeq (R), the results were E 234 per RV-case prevented, is an element of 2622 per RV-associated hospitalization avoided, and is an element of 142,732 per QALY gained. Variation of various parameters in sensitivity analyses showed effects on the ICERs without changing the overall trend of base-case results. When applying base-case results to the 2012 birthcohort in Germany with 80\\% vaccination coverage, an estimated 206,000-242,000 RV-cases and 18,000 RV-associated hospitalizations can be prevented in this birthcohort over five years for an incremental cost of 44.5-48.2 million is an element of. Conclusion: Our analyses demonstrate that routine RV-vaccination could prevent a substantial number of RV-cases and hospitalizations in the German healthcare system, but the saved treatment costs are counteracted by costs for vaccination. However, with vaccine prices reduced by similar to 62-66\\%, RV-vaccination could even become a cost-saving preventive measure. (C) 2014 Elsevier Ltd. All rights reserved.},\n\tnumber = {17},\n\tjournal = {Vaccine},\n\tauthor = {Aidelsburger, Pamela and Grabein, Kristin and Boehm, Katharina and Dietl, Markus and Wasem, Juergen and Koch, Judith and Ultsch, Bernhard and Weidemann, Felix and Wichmann, Ole},\n\tmonth = apr,\n\tyear = {2014},\n\tnote = {WOS:000336016700008},\n\tpages = {1964--1974},\n}\n\n","author_short":["Aidelsburger, P.","Grabein, K.","Boehm, K.","Dietl, M.","Wasem, J.","Koch, J.","Ultsch, B.","Weidemann, F.","Wichmann, O."],"key":"aidelsburger_cost-effectiveness_2014","id":"aidelsburger_cost-effectiveness_2014","bibbaseid":"aidelsburger-grabein-boehm-dietl-wasem-koch-ultsch-weidemann-etal-costeffectivenessofchildhoodrotavirusvaccinationingermany-2014","role":"author","urls":{},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":[],"search_terms":["cost","effectiveness","childhood","rotavirus","vaccination","germany","aidelsburger","grabein","boehm","dietl","wasem","koch","ultsch","weidemann","wichmann"],"title":"Cost-effectiveness of childhood rotavirus vaccination in Germany","year":2014}